CARCINOMA, NON-SMALL-CELL LUNG (NSCLC)
Clinical trials for CARCINOMA, NON-SMALL-CELL LUNG (NSCLC) explained in plain language.
Never miss a new study
Get alerted when new CARCINOMA, NON-SMALL-CELL LUNG (NSCLC) trials appear
Sign up with your email to follow new studies for CARCINOMA, NON-SMALL-CELL LUNG (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major trial tests promising new combo for tough lung cancers
Disease control Recruiting nowThis study is testing whether adding a new drug called Sigvotatug Vedotin to standard immunotherapy works better for advanced non-small cell lung cancer. It will involve 714 people with high levels of a specific protein (PD-L1) in their cancer cells. Half will get the new combina…
Matched conditions: CARCINOMA, NON-SMALL-CELL LUNG (NSCLC)
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Major trial tests new weapon against advanced lung cancer
Disease control Recruiting nowThis study is testing whether a new drug called PF-08634404, when combined with chemotherapy, works better than the current standard treatment (pembrolizumab with chemotherapy) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned…
Matched conditions: CARCINOMA, NON-SMALL-CELL LUNG (NSCLC)
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC